HS
NRIX icon

HighVista Strategies’s Nurix Therapeutics NRIX Stock Holding History

HighVista Strategies’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.94M Sell
203,739
-22,807
-10% -$389K 1.13% 26
2026
Q1 		$3.51M Buy
+226,546
New +$3.76M 0.97% 31
2022
Q1 		– Sell
-18,796
Closed -$544K – 92
2021
Q4 		$544K Hold
18,796
– – 0.43% 64
2021
Q3 		$563K Sell
18,796
-10,584
-36% -$327K 0.37% 70
2021
Q2 		$779K Buy
29,380
+10,158
+53% +$298K 0.55% 55
2021
Q1 		$598K Buy
+19,222
New +$727K 0.44% 59

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

HighVista Strategies's NRIX Position: Q2 2026 in Review

HighVista Strategies reduced its Nurix Therapeutics (NRIX) stake by 10% in Q2 2026, selling an estimated $389K and leaving 203,739 shares worth $4.94M. The position accounts for 1.13% of the portfolio, ranked #26.

HighVista Strategies first reported a position in NRIX in Q1 2021 and has held it in 6 quarters since. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • HighVista Strategies held 203,739 shares of Nurix Therapeutics worth $4.94M as of Q2 2026.
  • HighVista Strategies sold 22,807 Nurix Therapeutics shares in Q2 2026, an estimated $389K.
  • Nurix Therapeutics made up 1.13% of HighVista Strategies's portfolio in Q2 2026, its #26 holding.
  • HighVista Strategies first reported a position in Nurix Therapeutics in Q1 2021 and has held it in 6 quarters since.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.